New drug cocktail aims to shrink Hard-to-Treat gut tumors
NCT ID NCT07712094
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow to liver tumors. The study aims to see if this combination can slow tumor growth and improve outcomes as a first treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of ivonescimab (AK112), irinotecan, cisplatin, and optionally TACE (a procedure to block blood flow to liver tumors)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with metastatic digestive system neuroendocrine cancer, potentially improving tumor control and delaying disease progression.
- What could go wrong
- This is an early-phase (Phase 2) trial with a small number of participants (56), so results may not be generalizable. The combination therapy may cause significant side effects, and the added benefit of TACE is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baotou Cancer Hospital
Baotou, Inner Mongolia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First People's Hospital of Horqin District, Tongliao City
Tongliao, Inner Mongolia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin First Central Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University General Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin People's Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Third Central Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental combo aims to tackle Treatment-Resistant cancers
- New scan could spot hidden cancers
- New drug duo targets hard-to-treat cancers in early trial
- New biologic ZG006 targets tough lung and neuroendocrine cancers
- New drug BL-M14D1 targets tough cancers in early human trial
- New combo therapy shows promise for rare gut and lung cancers